echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Dongsong medicine and a new class of drugs hit the impact of a surge of 900% insulin

    Dongsong medicine and a new class of drugs hit the impact of a surge of 900% insulin

    • Last Update: 2021-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 20, the clinical application of two innovative drugs of Dongsian Pharmaceuticals was accepted by CDE contractor, which was accepted by hec 88473 injections of the new drug HEC and 3.3 new drugs, Degu insulin injections.
    in 2020, Dongsian Pharmaceuticals has 1 new class 3.3 drug application for the market, 9 new drug applications for clinical (7 for class 1 new drugs), of which 6 have been approved for clinical.
    source: CDE official heC88473 injection is the first new class 1 drug to submit a clinical application in 2021; Degu insulin injection is a new, ultra-long-effect insulin analogue,2 Global sales exceeded US$1.5 billion in 2019, and in the first half of 2020, terminal sales of urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) exceeded 50 million, up 922.6% YoY.
    In the past 2020, Dongsian Pharmaceuticals has applied for a new drug to be marketed for insulin glycerine injections, according to MiNet data, in the first half of 2020 China's public medical institutions terminal insulin glycerine sales of more than 3 billion yuan.
    addition, 7 new drugs of class 1 and 2 new drugs of class 2 were applied for clinical treatment, of which HEC95468 tablets, recombinant anti-VEGF humanized monoclonal antibody injection, HEC122505MsOH tablets, HEC89736PTSA.0.5H2O tablets, toluene sulphate nitrogen capsules, hydrochloric acid ionoid tablets have been approved clinically.
    2020 East Sunshine Drug Innovation Drug Declaration Source: MED2.0 China Drug Review Database Class 1 New Drugs, HEC89736PTSA.0.5H2O Tablets are the mouth of Dongsian Pharmaceuticals' independent research and development Highly selective PI3K pyrethroid inhibitors intended for the treatment of blood tumors, HEC122505 MSOH tablets as neurological drugs, have been initiated phase I clinically, and toluene sulfonate nigtini capsules and hydrochloric acid ivenione tablets have not been approved for the first time clinically.
    2 new drugs, recombinant anti-VEGF humanized monoclonal antibody injection for beva bead monobial-like drugs, currently has Zinda, Qilu two enterprises bio-similar drugs approved for listing.
    source: Mi Net database, CDE official website note: data statistics as of January 20, if there are omissions, welcome to point out!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.